Company intelligence / Profile preview

ImmunAdd Inc.

Taipei City, Taiwandnb.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ImmunAdd’s lead asset, IA‑05—a rationally designed synthetic saponin adjuvant—has demonstrated improved tolerability, stability, and long-term immune responses in preclinical studies compared to the widely used QS‑21. The company has received several patents for its proprietary technology but has not yet reported clinical results or entered human trials as of May 2025.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Vaccine adjuvants (saponin-based)Small moleculesDrug conjugatesFormulation technologies
Industry: Biotech

Drug pipeline

1 asset

IA-05

Pre-clinical

Indications: COVID-19, Influenza, Cancer

Partnerships

Seeking co-development partners among public R&D institutes, pharmaceutical/biotech companies, universities, vaccine manufacturers; no major partnerships publicly disclosed yet [3].

Beyond the preview

Go deeper on ImmunAdd Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunAdd Inc..

Explore the full profile